Identification and validation of AFAP1L1 as an immune-related prognostic biomarker in clear cell renal cell carcinoma

Key Points

• To identify and validate AFAP1L1 as a prognostic biomarker related to immune response in clear cell renal cell carcinoma (ccRCC).
• Conducted a biomarker identification study in ccRCC.
• Validated findings through statistical analyses.
• Evaluated the role of AFAP1L1 in immune response and tumor progression.
• AFAP1L1 was identified as a significant immune-related biomarker.
• Its levels correlate with ccRCC progression and patient outcomes.